Takeda Oncology
Kyla Ahn Stevens currently serves as an Oncology Territory Manager at Takeda Oncology, where a successful launch of a new colorectal cancer treatment has occurred across three academic centers and states. Prior experience includes a role as a Senior Hematology Consultant at Bristol Myers Squibb, promoting CAR T Cell Therapy and training on various cancer products. At Novartis Oncology, Kyla Ahn Stevens developed sales strategies in the breast cancer and neuroendocrine tumor markets, while at GSK, leadership included roles from Regional Sales Director to Sr. Sales Representative, focusing on vaccine promotion and account management. Academic credentials include a Master of Business Administration from Bellarmine University and a Bachelor of Business Administration from the University of Pikeville.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.